author-photo

John Hayslip

AbbVie

12

Papers

238

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
AML-062: Long-Term Follow-Up of a Phase 1/2 Study of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML)

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

2019 Blood
Show All
- Source
- Cite
- Save
Citations (29)
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

2019 Blood
Show All
- Source
- Cite
- Save
Citations (10)
Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure‐Response Analysis

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)